Third quarter 2023 net cash used in operating activities is expected to be in the range of ($2 million) to $18 million. This range includes the amount receivable in respect of the R&D tax credit in the UK, the timing for which is uncertain. We expect the full-year 2023 net cash used in operating activities to be in the range of $80 million to $90 million.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CMPS:
- COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights
- COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023
- Rising High: Exclusive talk with biotech company Tryp Therapeutics
- Compass Pathways publishes results of psilocybin treatment in anorexia nervosa
- First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine